AOD-9604 research guide

AOD-9604 in Yushan — Fat Loss Peptide Research Guide

AOD-9604 research guide for Yushan. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.

Skip to Sourcing Guide Order AOD-9604 →

Yushan Guide to AOD-9604 Research

Unlike everyday supplements stocked in every health store, AOD-9604 reaches researchers through a global research peptide market that Yushan residents reach through online vendors. The practical advantage of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers better verification tools than local retail ever could. A legitimate AOD-9604 supplier's COA should include HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all batch-matched to your order. What follows is a sourcing and quality evaluation guide built specifically around AOD-9604, covering everything a Yushan researcher needs before placing a first order.

Understanding AOD-9604 — Biology & Evidence

CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Yushan comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.

Sourcing Research-Grade AOD-9604

Assessing AOD-9604 vendors requires starting from the COA: request the batch-specific certificate before placing an order, not after. The HPLC purity trace is the most important document in the COA: it should show a large primary peak representing AOD-9604, with minimal secondary peaks representing impurities — purity should be stated as ≥98%. Community reputation in research forums is a valuable complement to COA verification — vendors with multi-year positive track records have proved themselves through consistent results. For Yushan researchers making a first AOD-9604 purchase: apply these quality criteria before ordering, begin with a small order, and check that batch numbers on your vial match the COA before use.

Order AOD-9604 — ships to Yushan
COA-verified · International tracking · Research grade
Order Now →

Safe Research Practices for AOD-9604

Research compound status for AOD-9604 means risk characterisation relies on animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Temperature excursions — even temporary temperature deviation — can partially degrade AOD-9604 without any obvious sign; always maintain cold chain and work with cold-shipped material. Verify the endotoxin level in your AOD-9604 batch COA before use in any in-vivo protocol — look for results reported in endotoxin units per mg or mL and compare against acceptable research limits for your application. Researchers combining AOD-9604 with other compounds should check the research literature for any reported interactions before proceeding with any multi-compound protocol.

Frequently Asked Questions

What is the clinical trial history of AOD-9604?

AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.

What is AOD-9604?

AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.

How does AOD-9604 differ from growth hormone?

AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.

Order AOD-9604 today
COA-verified · International shipping available
Order Now →